Lexapro: The First Victim of Part D?

A slowdown in sales of Forest's flagship antidepressant Lexapro left analysts confused: generic versions of Celexa seem to be weighing down the new product, but why did the impact suddenly arrive in the third quarter? A recently policy pronouncement from CMS may be a clue.